|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Markowitz SD and Bertagnolli MM: Molecular
basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koyanagi K, Bilchik AJ, Saha S, Turner RR,
Wiese D, McCarter M, Shen P, Deacon L, Elashoff D and Hoon DS:
Prognostic relevance of occult nodal micrometastases and
circulating tumor cells in colorectal cancer in a prospective
multicenter trial. Clin Cancer Res. 14:7391–7396. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bilchik AJ, Hoon DS, Saha S, Turner RR,
Wiese D, DiNome M, Koyanagi K, McCarter M, Shen P, Iddings D, Chen
SL, Gonzalez M, Elashoff D and Morton DL: Prognostic impact of
micrometastases in colon cancer: interim results of a prospective
multicenter trial. Ann Surg. 246:568–575. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/Akt/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Christofori G: New signals from the
invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stein U and Schlag PM: Clinical,
biological, and molecular aspects of metastasis in colorectal
cancer. Recent Results Cancer Res. 176:61–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pecina-Slaus N, Cicvara-Pecina T and Kafka
A: Epithelial-to-mesenchymal transition: possible role in
meningiomas. Front Biosci (Elite Ed). 13:889–896. 2012. View Article : Google Scholar
|
|
9
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 13:305–318. 2007. View Article : Google Scholar
|
|
10
|
Xu Y and Pasche B: TGF-beta signaling
alterations and susceptibility to colorectal cancer. Hum Mol Genet.
16:R14–R20. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eades G, Yao Y, Yang M, Zhang Y, Chumsri S
and Zhou Q: miR-200a regulates SIRT1 expression and epithelial to
mesenchymal transition (EMT)-like transformation in mammary
epithelial cells. J Biol Chem. 286:25992–26002. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gregory PA, Bracken CP, Smith E, Bert AG,
Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman
GJ, Shannon MF, Drew PA, Khew-Goodall Y and Goodall GJ: An
autocrine TGF-beta/ZEB/miR-200 signaling network regulates
establishment and maintenance of epithelial-mesenchymal transition.
Mol Biol Cell. 22:1686–1698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xiong M, Jiang L, Zhou Y, Qiu W, Fang L,
Tan R, Wen P and Yang J: The miR-200 family regulates
TGF-β1-induced renal tubular epithelial to mesenchymal transition
through Smad pathway by targeting ZEB1 and ZEB2 expression. Am J
Physiol Renal Physiol. 302:F369–F379. 2012. View Article : Google Scholar
|
|
14
|
Hur K, Toiyama Y, Takahashi M, Balaguer F,
Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR and Goel A:
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT)
in human colorectal cancer metastasis. Gut. 62:1315–1326. 2013.
View Article : Google Scholar :
|
|
15
|
Moustakas A and Heldin CH: Signaling
networks guiding epithelial-mesenchymal transitions during
embryogenesis and cancer progression. Cancer Sci. 98:1512–1520.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Y, Sato F, Yamada T, Bhawal UK,
Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada
K, Abiko Y, Kato Y and Kijima H: The BHLH transcription factor DEC1
plays an important role in the epithelial-mesenchymal transition of
pancreatic cancer. Int J Oncol. 41:1337–1346. 2012.PubMed/NCBI
|
|
17
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: an alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Comijn J, Berx G, Vermassen P, Verschueren
K, van Grunsven L, Bruyneel E, Mareel M, Huylebroeck D and van Roy
F: The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Mol Cell.
7:1267–1278. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Valencia-Sachez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar
|
|
20
|
Bagga S and Pasquinelli AE: Identification
and analysis of microRNAs. Genet Eng. 27:1–20. 2006. View Article : Google Scholar
|
|
21
|
Bar N and Dikstein R: miR-22 forms a
regulatory loop in PTEN/AKT pathway and modulates signaling
kinetics. PLoS One. 5:e108592010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leskelä S, Leandro-García LJ, Mendiola M,
Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo
A, de Santiago J and Robledo M: The miR-200 family controls
β-tubulin iii expression and is associated with paclitaxel-based
treatment response and progression-free survival in ovarian cancer
patients. Endocr Relat Cancer. 18:85–95. 2011. View Article : Google Scholar
|
|
23
|
Uhlmann S, Zhang J, Schwäger A,
Mannsperger H, Riazalhosseini Y, Burmester S, Ward A, Korf U,
Wiemann S and Sahin Ö: MiR-200bc/429 cluster targets plcγ1 and
differentially regulates proliferation and egf-driven invasion than
miR-200a/141 in breast cancer. Oncogene. 29:4297–4306. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li H, Tang J, Lei H, Cai P, Zhu H, Li B,
Xu X, Xia Y and Tang W: Decreased MiR-200a/141 suppress cell
migration and proliferation by targeting PTEN in Hirschsprung’s
disease. Cell Physiol Biochem. 34:543–553. 2014. View Article : Google Scholar
|
|
25
|
Gregory PA, Bert AG, Paterson EL, Barry
SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y and Goodall GJ:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park SM, Gaur AB, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang CH, Chen CL, More SV, Hsiao PW, Hung
WC and Li WS: The tetraindole SK228 reverses the
epithelial-to-mesenchymal transition of breast cancer cells by
up-regulating members of the miR-200 family. PLoS One.
9:e1010882014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ji HF, Li XJ and Zhang HY: Natural
products and drug discovery. EMBO Rep. 10:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chinese Pharmacopoeia Commission.
Pharmacopoeia of the Peoples Republic of China. 1. Chinese Medical
Science and Technology Press; Beijing: pp. 573–575. 2010
|
|
31
|
Lee KK, Kwong WH, Chau FT, Yew DT and Chan
WY: Pien Tze Huang protects the liver against carbon
tetrachloride-induced damage. Pharmacol Toxicol. 91:185–192. 2002.
View Article : Google Scholar
|
|
32
|
Chan WY, Chau FT, Lee KK, Kwong WH and Yew
DT: Substitution for natural musk in Pien Tze Huang does not affect
its hepatoprotective activities. Hum Exp Toxicol. 23:35–47. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin JM, Wei LH, Chen YQ, Liu XX, Hong ZF,
Sferra TJ and Peng J: Pien Tze Huang-induced apoptosis in human
colon cancer HT-29 cells is associated with regulation of the Bcl-2
family and activation of caspase 3. Chin J Integr Med. 17:685–690.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhuang QC, Hong F, Shen AL, Zheng LP, Zeng
JW, Lin W, Chen YQ, Sferra TJ, Hong ZF and Peng J: Pien Tze Huang
inhibits tumor cell proliferation and promotes apoptosis via
suppressing the STAT3 pathway in colorectal cancer mouse. Int J
Oncol. 26:1569–1574. 2012.
|
|
35
|
Shen AL, Hong F, Liu LY, Lin JM, Zhuang
QC, Hong ZF and Peng J: Effects of Pien Tze Huang on angiogenesis
in vivo and in vitro. Chin J Integr Med. 18:431–436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen AL, Hong F, Liu LY, Lin JM, Wei LH,
Cai QY, Hong ZF and Peng J: Pien Tze Huang inhibits the
proliferation of human colon carcinoma cells by arresting G1/S cell
cycle progression. Oncol Lett. 4:767–770. 2012.PubMed/NCBI
|
|
37
|
Shen AL, Chen YQ, Hong F, Lin JM, Wei LH,
Hong ZF, Sferra TJ and Peng J: Pien Tze Huang suppresses
IL-6-inducible STAT3 activation in human colon carcinoma cells
through induction of SOCS3. Oncol Rep. 28:2125–2130.
2012.PubMed/NCBI
|
|
38
|
Shen A, Lin J, Chen Y, Lin W, Liu L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang inhibits tumor angiogenesis
in a mouse model of colorectal cancer via suppression of multiple
cellular pathways. Oncol Rep. 30:1701–1706. 2013.PubMed/NCBI
|
|
39
|
Chen HW, Shen AL, Zhang YC, Chen YQ, Lin
JM, Lin W, Sferra TJ and Peng J: Pien Tze Huang inhibits
hypoxia-induced epithelial-mesenchymal transition in human colon
carcinoma cells via suppression of HIF-1 pathway. Exp Ther Med.
7:1237–1242. 2014.PubMed/NCBI
|
|
40
|
Wei LH, Chen PY, Chen YQ, Shen AL, Chen
HW, Lin W, Hong ZF, Sferra T and Peng J: Pien Tze Huang suppresses
the stem-like side population in colorectal cancer cells. Mol Med
Rep. 9:261–266. 2014.
|
|
41
|
Van Cutsem E and Costa F: Progress in the
adjuvant treatment of colon cancer: Has it influenced clinical
practice? JAMA. 294:2758–2760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lippman SM: The dilemma and promise of
cancer chemoprevention. Nat Clin Pract Oncol. 10:5232006.
View Article : Google Scholar
|
